top of page

Inhibikase Therapeutics develops novel formulation of risvodetinib

- New tablet formulation of risvodetinib approximately doubles drug exposure at same dose - Tablet formulation to be evaluated in the planned 12-month extension portion of the 201 trial

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use.

"As we advance our 201 trial evaluating risvodetinib at 50, 100 and 200 mg to treat Parkinson's disease, we have continued to expand our formulation and delivery capabilities," commented Dr. Milton Werner, President & CEO of Inhibikase. "We recently completed characterization of a novel tablet formulation that mimics the oral formulation we used to evaluate efficacy in validated animal models of Parkinson's disease. This novel tablet formulation nearly doubles drug exposure at steady-state for the same dose of risvodetinib, potentially enabling us to use a lower dose to reach therapeutic efficacy. This could improve the overall safety and tolerability of risvodetinib. In addition, the smaller size of these tablets compared to the capsules currently in use in the 201 clinical trial, the smaller tablets may overcome challenges patients have swallowing oral medication as a result of their disease. This new tablet formulation would be implemented in the planned 12 month extension of the 201 trial."

About Inhibikase ( Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Inhibikase is headquartered in Atlanta, Georgia with an office in Lexington, Massachusetts.

Source: Inhibikase


FC Global Strategies enables medical, pharma, healthcare, medical device and healthcare IT companies to achieve their business and financial goals

Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives.

If your company has business or financial objectives check out:

Medical and Pharma Insider is a program of FC Global Strategies.

Click here to schedule a call to discuss your company's business and financial goals.

FC Global Strategies' Contacts:

North America and Global

Jeffrey Friedland (Based in the US)

+1 646 450 8909

The Middle East, North Africa and Eastern Europe

David Krutonog (Based in Israel)

+972 50 974 3429

Southeast Asia, Asia-Pacific, Australia, and New Zealand

Ross Swan (Based in Singapore)

+65 9181 9472

Latin America

Claudio Hebling (Based in Brazil)

+55 19 99377 7482

South Asia, India, and Sri Lanka

Vincent Paul Joseph (Based in India)

+91 962 620 9090

bottom of page